New antifungals for the treatment of invasive mould disease
Clinical Microbiology and Infection · 2026
DOI: 10.1016/j.cmi.2026.03.035 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Microbiology and Infection, 2026. Verfasst von Nancy N Vuong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Antifungal Agents, Invasive Fungal Infections, Fungi. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Invasive fungal infections are emerging as a critical threat to healthcare, yet the disparity in development and approval of new antifungal agents has only recently been addressed. In 2022, the WHO published the first global priority list of fungal pathogens (Fungal Priority Pathogens List) in order to promote public health awareness, encourage research and development, and propose actions and strategies for stakeholders to target in combatting the rise of fungal infections. OBJECTIVES: This review provides a summary of recent data of recently approved and/or investigational antifungals targeted at invasive mould infections, collating updated information on clinical findings of antifungal agents with potential use or activity against moulds listed on the WHO Fungal Priority Pathogens List. SOURCES: A PubMed literature search 'Aspergillus fumigatus', 'Fusarium', 'Mucorales', 'Eumycetoma', 'Scedosporium', and 'Lomentospora' with names of antifungal agents 'rezafungin', 'ibrexafungerp', 'oteseconazole', 'opelconazole', 'fosmanogepix', 'olorofim', 'BAL2062', 'mandimycin', 'ATI-2307', 'MAT2203', 'TFF voriconazole', and 'miltefosine' was conducted. CONTENT: Preclinical and clinical trial data published within the last 5 years are discussed. The recent approvals of three new antifungals by the US Food and Drug Administration are a significant accomplishment in the advancement of antifungal therapies. Approvals, current indications, and investigations for rezafungin, ibrexafungerp, and oteseconazole as antimould agents are discussed. Additionally, information on fosmanogepix, opelconazole, and olorofim, as well as reformulated agents and those in the pipeline, is included. Clinical data, where available, were the primary focus of the article. IMPLICATIONS: Development of new antifungal agents is challenging because of limited target sites, emergence of resistance, and adverse toxicity profiles. However, clinical data from fosmanogepix, olorofim, and encochleated amphotericin B are promising in both clinical efficacy and safety for the treatment of invasive mould infections. These new agents offer alternative options for difficult-to-treat infections, while providing promising efficacy and improved safety outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Nursing, Memorial Hermann Greater Heights Hospital, Houston, TX, USA.
- Department of Pharmacy, Michigan Medicine, Ann Arbor, MI, USA; Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA; Division of Infectious Diseases, University of Michigan Med…
- Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: CRRausch@mdanderson.org.
Zitieren
APA
Vuong, N. N., McClung, D. R., Aitken, S. L., & Rausch, C. R. (2026). New antifungals for the treatment of invasive mould disease. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2026.03.035
Vancouver
Vuong NN, McClung DR, Aitken SL, Rausch CR. New antifungals for the treatment of invasive mould disease. Clinical Microbiology and Infection. 2026. doi:10.1016/j.cmi.2026.03.035
BibTeX
@article{Vuong2026,
author = {Vuong, Nancy N and McClung, David R and Aitken, Samuel L and Rausch, Caitlin R},
title = {New antifungals for the treatment of invasive mould disease},
journal = {Clinical Microbiology and Infection},
year = {2026},
doi = {10.1016/j.cmi.2026.03.035}
}
EUVIMED